Skip to main content
main-content

Gout and crystal arthropathies

Gout

12-05-2020 | Gout | News

ACR guidelines for gout management published

The American College of Rheumatology has issued updated guidelines for the management of gout.

23-04-2020 | Gout | News

Infection-related hospitalizations on the rise among people with gout

The rate of serious infections requiring hospitalization, particularly sepsis, is increasing among people with gout, US longitudinal study data show.

20-04-2020 | Gout | News

Dapansutrile ‘has substantial potential’ for treating gout flares

Findings from a proof-of-concept phase 2a trial provide preliminary evidence to suggest that dapansutrile, an inhibitor of the NLRP3 inflammasome, may be a promising therapeutic option for gout flares.

13-01-2020 | Gout | News

SGLT2 inhibitors linked to reduced gout risk in diabetes patients

People with type 2 diabetes who are treated with sodium-glucose cotransporter 2 inhibitors are less likely to develop gout than those given glucagon-like peptide-1 receptor agonists, researchers report.

18-12-2019 | Gout | News

Canagliflozin may reduce gout flare risk in people with type 2 diabetes

Treatment with the sodium-glucose cotransporter-2 inhibitor canagliflozin is associated with a reduction in serum urate concentration and gout flare risk among patients with type 2 diabetes, suggests a post-hoc analysis of the CANVAS Program trial.

03-12-2019 | Gout | News

Febuxostat and allopurinol may raise acute kidney injury risk

Febuxostat and allopurinol are associated with an elevated risk for acute kidney injury, according to study results published in Arthritis Research & Therapy.

11-11-2019 | Gout | News

Naproxen recommended over low-dose colchicine for gout flares

Naproxen and low-dose colchicine are similarly effective in the reduction of pain associated with gout flares, but patients receiving colchicine tend to experience more side-effects, show results from the multicenter, open-label CONTACT trial.

21-10-2019 | Gout | News

Achieving target sUA levels ‘should be a principal goal’ in hyperuricemic patients with gout

People with gout and hyperuricemia who achieve guideline-recommended serum uric acid levels below 0.36 mmol/L have lower risks for overall and cardiovascular mortality than those who do not meet this target, researchers report.

23-09-2019 | Gout | News

Modifiable risk factors account for substantial proportion of hyperuricemia cases

High BMI, non‐adherence to a DASH‐style diet, alcohol use, and diuretic use account for a substantial proportion of hyperuricemia cases in the US population, study findings indicate.

10-09-2019 | Gout | Editorial | Article

The 2018 updated EULAR recommendations for the diagnosis of gout: What's new, what's changed, and what's gone?

Editorial Board member Fernando Pérez-Ruiz summarizes the key changes in the 2018 updated EULAR recommendations for the diagnosis of gout.

The 2018 updated EULAR recommendations for the diagnosis of gout: What's new, what's changed, and what's gone?

Editorial Board member Fernando Pérez-Ruiz summarizes the key changes in the 2018 updated EULAR recommendations for the diagnosis of gout.

14-08-2019 | Gout | News

Vaccination may increase gout flare risk

The increased risk for gout flares following receipt of the aluminum-free recombinant zoster vaccine is not unique to this vaccine but is instead associated with vaccination in general, regardless of the adjuvant used, US researchers report.

19-07-2019 | Gout | News

Genetic loci influencing asymptomatic hyperuricemia to gout progression identified

A Japanese genome-wide association study has identified novel genetic loci associated with the susceptibility of gout in individuals with asymptomatic hyperuricemia.

European recommendations for the diagnosis of gout issued

EULAR has issued eight updated evidence-based recommendations to guide the diagnosis of gout.

10-06-2019 | Gout | Highlight | News

European recommendations for the diagnosis of gout issued

EULAR has issued eight updated evidence-based recommendations to guide the diagnosis of gout.

Using genetic studies to assess the impact of hyperuricemia in cardiometabolic and chronic kidney disease

Editorial Board member Fernando Pérez-Ruiz discusses the impact of hyperuricemia in cardiometabolic and chronic kidney disease, focusing on the role of genetic studies in showing a causal association between these conditions.

12-04-2019 | Gout | Editorial | Article

Using genetic studies to assess the impact of hyperuricemia in cardiometabolic and chronic kidney disease

Editorial Board member Fernando Pérez-Ruiz discusses the impact of hyperuricemia in cardiometabolic and chronic kidney disease, focusing on the role of genetic studies in showing a causal association between these conditions.

14-03-2019 | Gout | News

FDA approves oral colchicine for gout flare prophylaxis

Oral colchicine has been approved by the US FDA for the prevention of flares in people with gout.

22-02-2019 | Gout | News

FDA warns of increased death risk with febuxostat

The US FDA will update the prescribing information for the gout treatment febuxostat to include a boxed warning for death risk.

17-01-2019 | Gout | News

Anakinra may be a ‘viable treatment option’ for gout

Findings from a randomized trial suggest that treatment with the interleukin-1 receptor antagonist anakinra is noninferior to usual care for the treatment of gout flares.

Image Credits